CERo Therapeutics Inc.
(CERO)
undefined
undefined%
At close: undefined
0.06
0.52%
After-hours Jan 03, 2025, 05:58 PM EST
Company Description
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer.
Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors.
The company is based in South San Francisco, California.
CERo Therapeutics Inc.
| Country | United States |
| IPO Date | Nov 30, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Christopher B. Ehrlich M.B.A. |
Contact Details
Address: 201 Haskins Way South San Francisco, California United States | |
| Website | https://www.cero.bio |
Stock Details
| Ticker Symbol | CERO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001870404 |
| CUSIP Number | n/a |
| ISIN Number | US71902K1051 |
| Employer ID | 87-1088814 |
| SIC Code | 6770 |
Key Executives
| Name | Position |
|---|---|
| Christopher B. Ehrlich M.B.A. | Chief Executive Officer & Chair |
| Andrew Albert Kucharchuk M.B.A. | Chief Financial Officer & Director |
| Brian G. Atwood | President & Director |
| Dr. Kristen Pierce Ph.D. | Chief Development Officer & Director |
| Dr. Lawrence Corey M.D. | Co-founder & Head of Scientific Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 31, 2024 | 8-K | Current Report |
| Dec 23, 2024 | S-1 | Filing |
| Dec 17, 2024 | SCHEDULE 13G/A | [Amend] Filing |
| Dec 13, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Dec 13, 2024 | 4 | Filing |
| Dec 10, 2024 | 4 | Filing |
| Dec 09, 2024 | S-8 | Filing |
| Dec 06, 2024 | 8-K | Current Report |
| Dec 05, 2024 | 424B3 | Filing |
| Dec 05, 2024 | 424B3 | Filing |